Quick Answer
Jasper Therapeutics, Inc. reported Stockholders Equity of $4.15 million for the year ending 2025.
- Jasper Therapeutics, Inc. showed a decrease of -93.3% in Stockholders Equity from 2024 to 2025.
- This data is from Jasper Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $24.0 thousand | Q1 2020: -$6.17 million | Q2 2020: -$15.13 million | Q3 2020: -$25.64 million | Q1 2021: -$44.55 million | Q2 2021: -$52.60 million | Q3 2021: $78.60 million | Q1 2022: $68.11 million | Q2 2022: $58.78 million | Q3 2022: $47.57 million | Q1 2023: $125.20 million | Q2 2023: $110.21 million | Q3 2023: $94.13 million | Q1 2024: $113.23 million | Q2 2024: $100.31 million | Q3 2024: $83.68 million | Q1 2025: $42.24 million | Q2 2025: $23.50 million | Q3 2025: $11.57 million.
- Over the full 7 years of available data (2019 to 2025), Jasper Therapeutics, Inc.'s Stockholders Equity has grown by 187.7%.
- Historical annual values: Fiscal year 2025: $4.15 million | Fiscal year 2024: $61.67 million | Fiscal year 2023: $78.44 million | Fiscal year 2022: $35.99 million | Fiscal year 2021: $69.52 million | Fiscal year 2020: -$35.13 million | Fiscal year 2019: -$4.73 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: